{"entity":{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","aka":["OCTOPOD"],"tldr":"A phase 1/2 trial of THEO-260 in ovarian cancer, run by Theolytics Limited, now recruiting.","summary":"Trial of THEO-260 in Ovarian Cancer Patients is a phase 1/2 interventional study registered as NCT06618235 by Theolytics Limited, with 44 participants planned, started 2024-09-24 and due to reach its primary completion in 2028-06. Interventions recorded: THEO-260.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06618235","url":"https://clinicaltrials.gov/study/NCT06618235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","high-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["theo-260"],"companies":["theolytics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06618235","phase":"1/2","setting":"A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer","sponsor":"Theolytics Limited","started":"2024-09-24","startedType":"actual","enrolled":44,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06618235/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/"}],"company":[{"id":"theolytics","kind":"company","name":"Theolytics","route":"/companies/theolytics/"}]}}